Benjamin George Keselowsky

20120108468, May 3, 2012

Nov 2, 2011

13/373051

Benjamin George Keselowsky - Gainesville FL, US
Abhinav Prakash Acharya - Gainesville FL, US
Emina Huang - Gainesville FL, US
Edward William Scott - Gainesville FL, US
Matthew Carstens - Gainesville FL, US

University of Florida Research Foundation, Inc. - Gainesville FL

C40B 40/10
C40B 40/12
C40B 40/04

506 18, 506 15, 506 19

Embodiments of the present disclosure provide for arrays, systems, and methods for the analyzing cells, methods of making arrays, and the like.

20130287729, Oct 31, 2013

Oct 24, 2011

13/880778

Benjamin George Keselowsky - Gainesville FL, US
Abhinav Acharya - Atlanta GA, US
Michael J. Clare-Salzler - Gainesville FL, US
Mark A. Atkinson - Gainesville FL, US
Clive Henry Wasserfall - Gainesville FL, US
Chang Qing Xia - Gainesville FL, US
Todd M. Brusko - Gainesville FL, US

UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. - GAINESVILLE FL

A61K 9/50
A61K 47/48

424 852, 424489, 4242801, 424 855, 424 854, 4242781, 4241781, 424 851

The present invention provides antigen-specific, tolerance-inducing microparticles for the targeted delivery of therapeutic agents to immune cells. In addition, the present invention allows for sustained release of therapeutic agents for a prolonged period of time. Also provided are therapeutic uses of the present invention for the prevention and/or treatment of immune diseases and autoimmune disorders. In a specific embodiment, the present invention provides treatment for type 1 diabetes.

20110091510, Apr 21, 2011

Apr 30, 2009

12/936491

Tanmay P. Lele - Gainesville FL, US
Fan Ren - Gainesville FL, US
Benjamin George Keselowsky - Gainesville FL, US
Jiyeon Lee - Gainesville FL, US
Anand Gupte - Gainesville FL, US
Byung-Hwan Chu - Gainesville FL, US
Karl Zawoy - High Springs FL, US

A61K 9/00
A61K 31/727
A61K 38/02
A61K 33/24
A61K 31/407
C12N 5/071
A61P 43/00
B32B 9/00
C01G 9/02
C01G 23/047
C01B 33/02
C01B 21/06
A61L 33/00
B82Y 5/00
B82Y 40/00

424400, 514 56, 514 11, 424649, 514410, 435375, 428389, 428401, 428379, 428392, 4282921, 4282924, 4282974, 423622, 423610, 423348, 423409, 427 224, 977762, 977811, 977778, 977783, 977882, 977906

The subject invention concerns nanorods, compositions and substrates comprising nanorods, and methods of making and using nanorods and nanorod compositions and substrates. In one embodiment, the nanorod is composed of Zinc oxide (ZnO). In a further embodiment, a nanorod of the invention further comprises SiOor TiO. In a specific embodiment, a nanorod of the invention is composed of ZnO coated with SiO. Nanorods of the present invention are useful as an adhesion-resistant biomaterial capable of reducing viability in anchorage-dependent cells.

20230037160, Feb 2, 2023

Sep 27, 2022

17/953407

- Gainesville FL, US
Ida E. Svensson Berglund - Chicago IL, US
Benjamin G. Keselowsky - Gainesville FL, US
Malisa Sarntinoranont - Gainesville FL, US
Harpreet Singh Brar - Hillsboro OR, US
Hunter B. Henderson - Gainesville FL, US

A61L 27/04
C22C 23/00
A61L 27/54
A61L 27/58
A61K 33/06
A61L 31/14
A61L 31/02
A61L 31/16

Embodiments of the present disclosure provide for structures including an alloy of calcium, strontium, and magnesium.

20190218264, Jul 18, 2019

Oct 4, 2017

16/339585

- Gainesville FL, US
SABRINA FREEMAN - Gainesville FL, US
ANTONIETTA RESTUCCIA - Gainesville FL, US
MARGARET FETTIS - Gainesville FL, US
EVELYN R. BRACHO-SANCHEZ - Gainesville FL, US
SHAHEEN FARHADI - Gainesville FL, US
BENJAMIN G. KESELOWSKY - Gainesville FL, US

C07K 14/47
C12N 9/02

Provided herein are targeted effector fusion proteins, complexes thereof, and uses thereof. The targeted effector fusion proteins can include an effector protein that can be linked to a targeting moiety. Monomer targeted effector fusion proteins can form homogeneous or heterogeneous complexes. The targeted effector fusion proteins and complexes thereof can be formulated as pharmaceutical formulations. The targeted effector fusion proteins, complexes thereof, and formulations thereof can be administered to a subject in need thereof.

20180311344, Nov 1, 2018

Jul 16, 2018

16/036398

- Gainesville FL, US
Mark A. ATKINSON - Gainesville FL, US
Benjamin George KESELOWSKY - Gainesville FL, US
Young Mee YOON - Gainesville FL, US

A61K 39/39
A61K 47/34
A61K 39/00
A61K 38/19
A61K 39/35

The present invention provides materials and methods for modulating an immune response. In one embodiment, the present invention provides an initial artificial lymph-node homing environment, and a simultaneous, or subsequent, artificial spleen environment leading to the resolution of the activated immune responses. In one specific embodiment, the present invention can be used to prevent and/or treat pathogenic infection, cancer, allergenic reactions, and/or unwanted immune or auto-immune responses.

20170095590, Apr 6, 2017

Dec 16, 2016

15/381163

- Gainesville FL, US
Ida E. Svensson Berglund - Chicago IL, US
Benjamin G. Keselowsky - Gainesville FL, US
Malisa Sarntinoranont - Gainesville FL, US
Harpreet Singh Brar - Hillsboro OR, US
Hunter B. Henderson - Gainesville FL, US

A61L 27/04
A61K 33/06
A61L 27/58
C22C 23/00
A61L 27/54

Embodiments of the present disclosure provide for structures including an alloy of calcium, strontium, and magnesium.

20170080121, Mar 23, 2017

Dec 1, 2016

15/366263

- Gainvesville FL, US
Harpreet Singh Brar - Hillsboro OR, US
Ida E. Svensson Berglund - Chicago IL, US
Malisa Sarntinoranont - Gainesville FL, US
Benjamin G. Keselowsky - Gainesville FL, US

A61L 27/04
A61L 31/02
C22C 23/00
A61L 27/54
A61L 31/16
A61L 27/58
A61L 31/14

Disclosed herein is a non-toxic, bioresorbable, magnesium based alloy for use in production of implants. Specifically exemplified herein are alloy embodiments useful for orthopedic implants. Also disclosed are alloy materials that incorporate magnesium, calcium and strontium.